🎯 Milestone Achieved: We’ve successfully identified active compounds in our 2D cardiomyocyte assay, for our disease modifying approach to heart failure with preserved ejection fraction (HFpEF). A significant step forward in our drug discovery journey!
✨ Look at our heart cells beat!
Using our iPSC-derived cardiomyocytes, we have developed and validated an in-house assay tailored to test disease modifying effects of small molecule inhibitors to a first-in-class-target, within a human heart-specific system.
We’re thrilled to share that multiple active compounds have been identified, bringing us closer to unlocking new therapeutic possibilities.
This progress is a testament to our team’s innovation, dedication, and the power of cutting-edge science. It’s an incredible way to wrap up 2024, and we’re excited for what lies ahead in 2025!
Here’s to more milestones and breakthroughs in the journey toward impactful healthcare solutions.